Price: $11.9400
$0.12
1.015%
|
Day's High:
| $11.99
| Week Perf:
| -0.25 %
|
Day's Low: |
$ 11.72 |
30 Day Perf: |
-1.08 % |
Volume (M): |
16,558 |
52 Wk High: |
$ 13.62 |
Volume (M$): |
$ 197,705 |
52 Wk Avg: |
$10.30 |
Open: |
$11.72 |
52 Wk Low: |
$8.74 |
|
|
Market Capitalization (Millions $) |
9,423 |
Shares
Outstanding (Millions) |
789 |
Employees |
37,000 |
Revenues (TTM) (Millions $) |
15,427 |
Net Income (TTM) (Millions $) |
55 |
Cash Flow (TTM) (Millions $) |
-269 |
Capital Exp. (TTM) (Millions $) |
377 |
Viatris Inc
Viatris Inc. is a global pharmaceutical company focused on providing affordable access to high-quality medicines for patients worldwide. The company was formed as a result of the merger between Mylan N.V. and Pfizeres Upjohn business in November 2020. Headquartered in Pittsburgh, Pennsylvania, Viatris has operations in more than 165 countries, and its medicines are used by more than one billion people globally.
The company has a diverse portfolio of products that span across various therapeutic areas such as cardiovascular, central nervous system, dermatology, gastroenterology, HIV/AIDS, and oncology. Some of its well-known brands include Lipitor, Advil, Celebrex, and Viagra.
Viatris employs more than 45,000 people worldwide and has a strong commitment to sustainability and corporate social responsibility. The company strives to reduce its environmental footprint by promoting responsible manufacturing practices, sourcing renewable energy, and reducing water usage.
In terms of financials, Viatris had revenues of $11.9 billion in 2020, and its products are sold in more than 165 countries worldwide. The company's market capitalization as of August 2021 is approximately $15 billion.
Viatris leadership is committed to driving growth and innovation by investing in its portfolio, technology, and partnerships with other companies. The company's leadership team is composed of experienced executives with extensive experience in the pharmaceutical industry, including Heather Bresch, CEO, and Rajiv Malik, President.
Overall, Viatris is a global pharmaceutical company focused on delivering high-quality medicines at affordable prices to patients worldwide. The company's diverse portfolio of products, global reach, commitment to sustainability, and strong leadership all contribute to its success and continued growth.
Company Address: 1000 Mylan Boulevard Canonsburg 15317 PA
Company Phone Number: 514-1800 Stock Exchange / Ticker: NASDAQ VTRS
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Viatris Inc
Viatris Inc: A Promising Turnaround Story Viatris Inc, a major player in the pharmaceutical industry, recently released its financial results for the fiscal period ending December 31, 2023. While the numbers may initially appear disappointing, a closer look reveals a company that is taking strategic steps to improve its financial position and set itself up for a strong future. During the fiscal period, Viatris slipped into a deficit of $0.97 per share, compared to earnings of $0.82 per share in the previous year. Additionally, the company saw a decrease in revenue by 0.998%, with a total of $3.84 billion for the period. The net deficit for the period amounted to $765.6 million, a significant drop from the $1,011.2 million profit in the previous year.
|
Personnel Announcements
Published Fri, Dec 15 2023 9:45 PM UTC
PITTSBURGH, Dec. 15, 2023 - Viatris Inc. (NASDAQ: VTRS), a global healthcare company, publicly disclosed its preparations for Phase 2 of its strategic plan by appointing Theodora Doretta Mistras as Chief Financial Officer and Philippe Martin as Chief R&D Officer. Mistras is set to assume the role on March 1, 2024, joining Viatris after a successful career in the finance...
|
Viatris Inc
Viatris Inc, a major player in the pharmaceutical preparations industry, has witnessed contrasting trends in its stock performance. While the stock declined by -4.33% during the preceding month, it saw a 4.86% increase in the past five trading days. The company also traded 6.1% above its 52-week low. However, these positive stock movements come in the backdrop of soft financial results reported by Viatris Inc for the financial period closing on September 30, 2023. This article will explore the implications of these contrasting factors on the company's future. 1. Revenue and Profitability: Viatris Inc faced a revenue decline of -3.342% year-on-year, with revenues decreasing to $3.94 billion. This presents a concerning trend compared to other players in the Major Pharmaceutical Preparations industry, who reported revenue gains for the same period. Furthermore, the bottom-line (net income) of Viatris Inc also experienced a significant setback, dropping by -6.9% to $0.27 per share. Profitability indicators such as operating margin and net margin also saw reductions, indicating potential challenges ahead.
|
Viatris Inc
Introduction Viatris Inc, a major player in the pharmaceutical preparations sector, recently announced its financial performance for the second quarter of 2023. The company experienced a decline in both income and revenue, resulting in a decrease of 15.38% and 4.814%, respectively, year on year. While this decline is significant, it is essential to note that Viatris Inc was relative to the remainder of its sector, which saw a top-line improvement during the same period. Earnings Analysis Comparing the second quarter of 2023 to the previous reporting period, Viatris Inc witnessed a growth in revenue of 5.082%, reaching $3.92 billion. Additionally, earnings per share increased by 15.79% from $0.19 per share to $0.22 per share, demonstrating a positive trend in the company's financials.
|
Viatris Inc
Viatris Inc is a global healthcare company that specializes in the manufacturing and distribution of generic drugs. The company was formed in 2020 after a merger between Mylan and Pfizer Inc.'s Upjohn division. With a strong presence in over 165 countries and territories, Viatris Inc is one of the largest pharmaceutical companies in the world. The recent financial update from Viatris Inc for the first quarter of 2023 has been received with mixed reactions from market analysts. While the company's return on assets (ROA) of 3.83% is above its average ROA of 1.49%, there are concerns regarding the decline in net income, which led to a decrease in the ROA compared to the previous quarter. Additionally, Viatris Inc's ROA is lower than that of 72 other healthcare companies.
|
Per Share |
Current |
Earnings (TTM) |
-0.29 $ |
Revenues (TTM) |
19.55 $
|
Cash Flow (TTM) |
- |
Cash |
1.26 $
|
Book Value |
25.93 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.29 $
|
Revenues (TTM) |
19.55 $ |
Cash Flow (TTM) |
- |
Cash |
1.26 $
|
Book Value |
25.93 $ |
Dividend (TTM) |
0 $ |
|
|
|
|